KaloBios Pharmaceuticals, Inc. announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company's board of directors. The company has named Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.50% |
|
0.00% | -83.33% |
May. 01 | Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc. | CI |
Apr. 12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-83.33% | 23.82K | |
+2.99% | 94.76B | |
-4.34% | 37.58B | |
-10.41% | 33.3B | |
+75.79% | 27.92B | |
-14.61% | 15.85B | |
-3.46% | 13.79B | |
-12.31% | 11.51B | |
+184.77% | 10.9B | |
-54.13% | 9.27B |
- Stock Market
- Equities
- HGENQ Stock
- News Humanigen, Inc.
- KaloBios Pharmaceuticals, Inc. Announces Management Changes